Nazareth Hospital EMMS
Nazareth, Al Wadi Al Jawani 1611, 16100, Israel
NCT Number: NCT06358365
To demonstrate safety and performance of AquaPass System for improving fluid balance in hemo-dialysis patients, by increasing fluid loss via the skin.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nazareth, Al Wadi Al Jawani 1611, 16100, Israel
This study requires several investigational tests, exams, and data collection procedures to be performed by the participants. These procedures are listed in abbreviated format in the Schedule of Assessments/Activities table. The final eligibility of the trial will be confirmed after a 2-hour acclimatization session. The trial-specific procedures must not be performed until the participant has signed a written informed consent form, which has been approved by the site's Institutional Review Board.
The investigator or designee, who is trained in the clinical investigation plan, will explain the nature and scope of the trial to the participant. They will also discuss the potential risks and benefits of participation and answer any questions the participant may have. If the participant agrees to participate, they must sign the informed consent form. The investigator/designee must also sign the form before the participant can be enrolled in the trial. Any additional persons required by the site's Institutional Review Board to sign the informed consent form must also comply.
Each participant's study duration will be approximately 8 weeks. The study duration will be identical for all participants, as follows:
Screening Period: This period will last up to 7 days, during which time the participant's eligibility for the trial will be determined.
Observation Period: This period will last 3 weeks, during which the participant will come to the medical study center for weekly assessments.
Procedure Period: This period will last 4 weeks, during which time the participant will undergo 2-3 procedures with the AquaPass device each week. These procedures will be in addition to their regular hemodialysis treatment. The participant will undergo 2 procedures during the weekend, and each procedure will last 3-8 hours.
Follow-Up: This period will last 7(±1) days from the last procedure. During this period, the participant's health status will be monitored.
In summary, the study requires participants to undergo several investigational tests, exams, and data collection procedures. The study duration for each participant will be approximately 8 weeks, during which time they will undergo a screening period, observation period, procedure period, and follow-up period. All participants must provide written informed consent before any trial-specific procedures can be performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
Time frame: Up to 50 days
weight at the end of the last Hemodialysis session before AquaPass therapy subtracted from the weight in the morning of the first Hemodialysis session of the week after AquaPass therapy.
Time frame: Up to 60 Days
Safety evaluation of device-related adverse effects
Time frame: Up to 50 days
Changes in biomarkers of congestion
Time frame: Up to 50 days
Changes in Blood Urea Nitrogen levels
Time frame: up to 50 days
change in the quality of life measured by the Kansas City Cardiomyopathy Questionnaire. In this questionnaire the minimum score is '0' and the maximum is '100', and higher scores represent a better outcome for the patient.
Time frame: up to 28 days
Evaluation of the changes in ultrafiltration rates between the control phase and the Aquapass phase in the first dialysis session after the long interdialytic period
AquaPass Medical Ltd.
Industry
Evaluation of the Safety & Performance of the Aquapass -Medical Device, for Enhancing Fluid Transfer Through the Skin, by Increased Sweat Rate, on Hemodialysis Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04334707
Acute Kidney Failure, Acute Kidney Injury
Tucson, Arizona, United States
View Trial DetailsNCT07645365
Acute Kidney Failure, Acute Kidney Injury
Antalya, konyaaltı, Turkey (Türkiye)
View Trial DetailsNCT07132619
Acute Kidney Failure, Acute Kidney Injury
Istanbul, Kartal, Turkey (Türkiye)
View Trial DetailsNCT05384899
Acute Kidney Failure, Acute Kidney Injury
New Haven, Connecticut, United States
View Trial Details